xmlns:atom="http://www.w3.org/2005/Atom" xmlns:atom="http://www.w3.org/2005/Atom"
specific features of the clinical trial population, such as subjects not able to give informed consent, minors and pregnant or breastfeeding women;
whether the clinical trial involves the first administration of a new active substance to humans;
whether scientific advice relating to the clinical trial or the investigational medicinal product has been given by the Agency, a Member State or a third country;
whether the clinical trial is part or is intended to be part of a Paediatric Investigation Plan (PIP) as referred to in Title II, Chapter 3, of Regulation (EC) No 1901/2006 (if the Agency has already issued a decision on the PIP, the cover letter contains the link to the decision of the Agency on its website);
whether investigational medicinal products or auxiliary medicinal products are a narcotic, psychotropic or radiopharmaceutical;
whether the investigational medicinal products consist of or contain a genetically-modified organism or organisms;
whether the sponsor has obtained an orphan designation for the investigational medicinal product for an orphan condition;
a comprehensive list, including the regulatory status, of all investigational medicinal products and a list of all auxiliary medicinal products; and
a list of medical devices which are to be investigated in the clinical trial but which are not part of the investigational medicinal product or products, together with a statement as to whether the medical devices are CE-marked for the intended use.